Person: ÜNVER, OLCAY
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÜNVER
First Name
OLCAY
Name
6 results
Search Results
Now showing 1 - 6 of 6
Publication Open Access Depression, anxiety, and sleep quality of caregivers of children with spinal muscular atrophy(2023-03-01) ERGENEKON, ALMALA PINAR; YILMAZ YEĞİT, CANSU; SELÇUK, MERVE; KARABULUT, ŞEYDA; ÖZTÜRK THOMAS, GÜLTEN; ERDEM ERALP, ELA; ÜNVER, OLCAY; KARADAĞ, BÜLENT TANER; GÖKDEMİR, YASEMİN; ERGENEKON A. P., Gumus Z., YILMAZ YEĞİT C., Cenk M., Gulieva A., Kalyoncu M., SELÇUK M., KARABULUT Ş., ÖZTÜRK G., ERDEM ERALP E., et al.BackgroundThe aim of this study was to evaluate the prevalence of anxiety, depression, sleep, and associated factors in caregivers of children with spinal muscular atrophy (SMA). Materials and MethodsBeck Depression Inventory (BDI), the State-Trait Anxiety Inventory-State (STAI-S), the State-Trait Anxiety Inventory-Trait (STAI-T), and Pittsburgh Sleep Quality Index (PSQI) were used to assess the anxiety, depression, and sleep quality of the caregivers of children with SMA. Higher scores indicated worse outcome for all three questionnaires. ResultsFifty-six caregivers of children with SMA were included in the study. Median age of children was 6 (3.2-10) years and mean age of the caregivers was 37.0 +/- 6.5 years. Median scores of the BDI, STAI-S, STAI-T, and PSQI were 12 (7.2-17), 35.5 (31-44), 40.5 (35-48), and 7.0 (5.0-10.0), respectively. There was a positive correlation between BDI and PSQI scores (p < 0.05). There was a negative correlation between the age of the caregivers and PSQI, BDI, STAI-T scores (p = 0.01, r = -0.341; p = 0.006, r = -0.364; p = 0.003, r = -0.395, respectively). There was a negative correlation between the age of the patients and the PSQI scores of the caregivers (p = 0.01, r = -0.33). There was a negative correlation between BDI scores and household income (p = 0.01, r = -0.34). ConclusionCaregivers of children with SMA had elevated depression and anxiety levels and they also had decreased sleep quality. Economic and social support resources are needed to help caregivers of those children.Publication Open Access Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen(2022-01-01) ERGENEKON, ALMALA PINAR; ÖZTÜRK THOMAS, GÜLTEN; ÜNVER, OLCAY; TÜRKDOĞAN, DİLŞAD; KARADAĞ, BÜLENT TANER; ERDEM ERALP, ELA; ERGENEKON A. P., YILMAZ YEĞİT C., Cenk M., GÖKDEMİR Y., ERDEM ERALP E., ÖZTÜRK G., ÜNVER O., Coskun O. K., Saygi E. K., TÜRKDOĞAN D., et al.Background Respiratory failure is the leading cause of mortality in spinal muscular atrophy type 1 (SMA1) children. The current study aims to evaluate the effect of nusinersen treatment on respiratory outcome of the patients with SMA1. Methods In this retrospective, single-center study, 52 SMA1 patients treated with nusinersen were included in the analysis. Patients were divided into two groups based on their age at the time of their first nusinersen treatment (Group 1: 6 months). Respiratory outcome on the 180th day of treatment is defined as the type of ventilation support (spontaneous breathing, noninvasive ventilation (NIV), and tracheostomized or intubated on invasive mechanical ventilation). Demographic data, respiratory outcome, and Children\"s Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores were obtained from medical records. Results On the 180th day of treatment, 46 of the 52 (88.4%) children were alive. Prevalence of the mortality was similar in both groups (P = 0.65). The comparison of respiratory outcome in patients between group 1 and group 2 was as follows: spontaneous breathing, 7 (43.7%) versus 4 (13.3%) (P = 0.03); NIV = 16 h/day. There were significant improvements in Children\"s Hospital of Philadelphia Infant Test of Neuromuscular Disorders scores of the patients at day 180 in comparison with the baseline (P < 0.001). Conclusions Early initiation of nusinersen treatment in SMA1 patients may alter the disease\"s natural course.Publication Open Access The outcome of two SMA cases treated with nusinersen at seven hours and at three days of life: the earliest ever(2022-07-01) ÜNVER, OLCAY; ESİM BÜYÜKBAYRAK, ESRA; GÖKDEMİR, YASEMİN; MEMİŞOĞLU, ASLI; Ünver O., Çelik T., Memişoğlu A., Büyükbayrak E., Tülin Şimşek F., Öztürk G., Eser G., Saygı E. K., Gökdemir Y., Aktekin B., et al.New molecular therapies are available for the treatment of spinal muscular atrophy (SMA) but early intervention is required. We report two cases that were diagnosed prenatally, where treatment with nusinersen was initiated within 7 h and three days respectively. The children were followed up for 13 months and almost six years respectively. Both children have developed within entirely normal centiles, indicating that initiating treatment immediately after birth, as in these cases, is essential for a good outcome.Publication Open Access Effect of Nusinersen treatment on motor functions in children and adolescents with spinal muscular atrophy who gave a break to physiotherapy during covid-19 pandemic(2022-01-01) TÜRKDOĞAN, DİLŞAD; KARADAĞ SAYGI, NAİME EVRİM; ÜNVER, OLCAY; Ozturk G., Saygi E. K., ÜNVER O., TÜRKDOĞAN D.Publication Open Access Stress-induced childhood onset neurodegeneration with ataxia and seizures (condsias) presenting with torticollis attacks: phenotypic variability of the same mutation in two turkish patients(2022-03-01) ÖZTÜRK THOMAS, GÜLTEN; ÜNVER, OLCAY; AKBEYAZ, İSMAİL HAKKI; EKİNCİ, GAZANFER; TÜRKDOĞAN, DİLŞAD; Ozturk G., Ayaz A., Topcu Y., Akyuz G., ÜNVER O., AKBEYAZ İ. H. , EKİNCİ G., TÜRKDOĞAN D.Publication Metadata only Akut görme kaybı ile başvuran pediatrik hastalardaki bulgularımız(2022-04-23) TIRAŞ, NİMET ZEYNEP; DERİCİOĞLU, VOLKAN; AKBEYAZ, İSMAİL HAKKI; ÜNVER, OLCAY; Tiraş N. Z. , Dericioğlu V., Akbeyaz I. H. , Ünver O.GİRİŞVE AMAÇ:Görme kaybı ile başvuran pediatrik hastaların demografik verileri, verilen tedavileri ve tanılarını incelemek.YÖNTEM:Marmara Üniversitesi Hastanesi acil servisine 2021 yılı içerisinde optik sinir veya nörolojik kaynaklı görme keskinliği veya görme alanı kaybı ile başvuran hastalar çalışmaya dahil edildi. Diğer oftalmolojik nedenli görme kayıpları çalışmadan dışlandı. Hastaların demografik verileri, manyetik rezonans görüntülemeleri (MRG), en iyi düzeltilmişgörme keskinlikleri (EİDGK) (logMAR), oftalmolojik ve nörolojik muayenelerine ek olarak verilen tedaviler ve sonuç tanıları incelendi.BULGULAR:Çalışmaya 25 hasta dahil edildi. Hastaların ortalama yaşı 13.8±3.2 yıldı ve 15 (%60) hasta kız çocuğuydu. Hastalardan 11’i (%44) unilateral, 14’ü (%56) bilateral görme kaybı ile başvurdu. Hastaların %28’inde (n=7) ağrılı görme kaybı bulunurken, %44’ünde (n=11) eşlik eden ek nörolojik semptomlar vardı.İlk başvuru anında 15 hastada (%60) optik disk kabarıklığı mevcuttu. Beyin MRG değerlendirilmesinde 9 hastada (%36) optik sinirin orbital kısmında kontrast tutulumu izlenirken, ek kraniyal patolojik bulgu 11 hastada (%44) görüldü. Onbeşhastaya (%60) uygulanan lomber ponksiyonda ortalama açılışbasıncı 28.27 ± 23 cmH2O olarak bulundu. Hastaların 14’üne (%56) intravenöz metilprednizolon, 5’ine (%20) asetazolomid ve boşaltıcı LP uygulanırken, 6 hasta (%24) destek tedavisi ile takip edildi. Toplam 41 gözün başvuru anındaki ortalama EİDGK 1.02±1.09 logMAR ve sonuç EİDGK 0.48±0.79 logMAR olarak bulundu (p=0.001). Takiplerde hastaların 8’ine (%32) idiyopatik optik nörit, 5’ine (%20) idiyopatik intrakraniyal hipertansiyon (IIH), 4’üne (%16) multiple skleroz (MS), 3’er hasta (%12) metabolik ve herediter optik nöropati, 1 hastaya (%4) MOG ilişkili optik nörit ve 1 hastaya (%4) iskemik optik nöropati nedeniyle görme kaybı tanısı konuldu.TARTIŞMA VE SONUÇ:Acil servise başvuran pediyatrik görme kayıplarının en sık nedenini idiyopatik optik nörit oluşturmakta ve bunu IIH ve MS takip etmektedir.